Pertuzumab: Difference between revisions
Carlo Banez (talk | contribs) - link to FDA information |
No edit summary |
||
| Line 12: | Line 12: | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = NA |
| ChemSpiderID = NA |
||
| tradename = Perjeta |
| tradename = Perjeta; Omnitarg |
||
| licence_US = Pertuzumab |
| licence_US = Pertuzumab |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| Line 51: | Line 51: | ||
[[Image:Pertuzumab-HER2 complex 1S78.png|thumb|300px|The structure of [[HER2]] and pertuzumab]] |
[[Image:Pertuzumab-HER2 complex 1S78.png|thumb|300px|The structure of [[HER2]] and pertuzumab]] |
||
'''Pertuzumab''' (also called '''2C4''', trade name '''Perjeta''') is a [[monoclonal antibody]]. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to [[HER2]], it inhibits the [[protein dimer|dimer]]ization of HER2 with other HER receptors, which is hypothesized to result in slowed [[cancer|tumor]] growth.<ref name="JCO-deBono">{{cite journal|last = de Bono|first = Johann S.|title=Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer|journal = Journal of Clinical Oncology|volume=25|issue=3|pages=257–262|date=20 January 2007|id=|doi=10.1200/JCO.2006.07.0888|pmid=17235043|last2 = Bellmunt|first2 = J|last3 = Attard|first3 = G|last4 = Droz|first4 = JP|last5 = Miller|first5 = K|last6 = Flechon|first6 = A|last7 = Sternberg|first7 = C|last8 = Parker|first8 = C|last9 = Zugmaier|first9 = G}}</ref> Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012.<ref>{{cite press release|url=http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=14007 |title=FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer |publisher=Genentech |accessdate=2012-06-09}}</ref> |
'''Pertuzumab''' (also called '''2C4''', trade name '''Perjeta''') is a [[monoclonal antibody]]. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to [[HER2]], it inhibits the [[protein dimer|dimer]]ization of HER2 with other HER receptors, which is hypothesized to result in slowed [[cancer|tumor]] growth.<ref name="JCO-deBono">{{cite journal|last = de Bono|first = Johann S.|title=Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer|journal = Journal of Clinical Oncology|volume=25|issue=3|pages=257–262|date=20 January 2007|id=|doi=10.1200/JCO.2006.07.0888|pmid=17235043|last2 = Bellmunt|first2 = J|last3 = Attard|first3 = G|last4 = Droz|first4 = JP|last5 = Miller|first5 = K|last6 = Flechon|first6 = A|last7 = Sternberg|first7 = C|last8 = Parker|first8 = C|last9 = Zugmaier|first9 = G}}</ref> Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012.<ref>{{cite press release|url=http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=14007 |title=FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer |publisher=Genentech |accessdate=2012-06-09}}</ref> Pertuzumab was developed at [[Genentech]] and is now owned by [[Hoffmann-La Roche|Roche]] which acquired Genentech in 2009. |
||
==Clinical trials== |
|||
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.<ref>[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005</ref> |
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.<ref>[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005</ref> |
||
Revision as of 20:37, 16 July 2012
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| Trade names | Perjeta; Omnitarg |
| License data |
|
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[2] Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012.[3] Pertuzumab was developed at Genentech and is now owned by Roche which acquired Genentech in 2009.
Clinical trials
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[4]
The dosage of pertuzumab used in the pivotal phase III CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial was as follows: IV 840 mg loading dose followed by IV 420 mg every three weeks.[5]
The pharmacokinetics of intravenous pertuzumab appear to be unaffected by age and no drug-drug interaction has been reported with docetaxel. The pharmacokinetics and pharmacodynamics of pertuzumab have recently been summarized in a review by Gillian Keating.[5]
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects in the randomized, double-blind, multinational, phase III CLEOPATRA trial.[6]
Intravenous pertuzumab is currently being evaluated in patients with breast cancer in the following trials: MARIANNE (advanced breast cancer), NEOSPHERE (early breast cancer), TRYPHAENA (HER2-positive stage II/III breats cancer) and APHINITY (HER2-positive nonmetastatic breast cancer).[5]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ de Bono, Johann S.; Bellmunt, J; Attard, G; Droz, JP; Miller, K; Flechon, A; Sternberg, C; Parker, C; Zugmaier, G (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043.
- ^ "FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer" (Press release). Genentech. Retrieved 2012-06-09.
- ^ Genentech press release - May 15, 2005
- ^ a b c Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012 Feb 12; 72 (3): 353-60.Link text
- ^ Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012 Jan 12; 366 (2): 109-19. Link text
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
10.1056/NEJMoa1113216